Merck & Co Inc
MRK78.560USD
+0.940+1.21%
Cierre 09/26, 16:00（ET）Cotizaciones retrasadas 15 min
196.65BCap. mercado
11.99P/E TTM
Más Datos de Merck & Co Inc Compañía
Merck & Co., Inc. is a research-intensive biopharmaceutical company engaged in research to deliver health solutions that advance the prevention and treatment of diseases in people and animals. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines. The Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. It is also engaged in developed a novel class of small molecules that target cancer cells lacking expression of a key DNA repair protein called O6-methylguanine methyl transferase.
Información de la empresa
Símbolo de cotizaciónMRK
Nombre de la empresaMerck & Co Inc
Fecha de salida a bolsaJan 01, 1941
Director ejecutivoMr. Robert M. (Rob) Davis
Número de empleados75000
Tipo de seguridadOrdinary Share
Fin del año fiscalJan 01
Dirección126 East Lincoln Avenue
CiudadRAHWAY
Bolsa de valoresNYSE Consolidated
PaísUnited States of America
Código postal07065
Teléfono19087404000
Sitio Webhttps://www.merck.com/
Símbolo de cotizaciónMRK
Fecha de salida a bolsaJan 01, 1941
Director ejecutivoMr. Robert M. (Rob) Davis
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Robert M. (Rob) Davis
Mr. Robert M. (Rob) Davis
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
443.60K
--
Mr. Sanat Chattopadhyay
Mr. Sanat Chattopadhyay
Executive Vice President and President - Merck Manufacturing Division
Executive Vice President and President - Merck Manufacturing Division
185.33K
+17.90%
Mr. Chirfi Guindo
Mr. Chirfi Guindo
Senior Vice President, Chief Marketing Officer - Human Health
Senior Vice President, Chief Marketing Officer - Human Health
85.34K
+28.11%
Dr. Dean Y. Li, M.D., Ph.D.
Dr. Dean Y. Li, M.D., Ph.D.
Executive Vice President, President - Merck Research Laboratories
Executive Vice President, President - Merck Research Laboratories
79.59K
+0.92%
Ms. Jennifer L. Zachary
Ms. Jennifer L. Zachary
Executive Vice President, General Counsel
Executive Vice President, General Counsel
53.42K
+90.81%
Mr. Joseph Edward Romanelli
Mr. Joseph Edward Romanelli
Senior Vice President, President - MSD International Human Health
Senior Vice President, President - MSD International Human Health
22.91K
+5.27%
Ms. Patricia F. Russo
Ms. Patricia F. Russo
Independent Director
Independent Director
13.15K
--
Mr. Thomas Henry (Tom) Glocer, J.D.
Mr. Thomas Henry (Tom) Glocer, J.D.
Lead Independent Director
Lead Independent Director
5.10K
--
Mr. Inge G. Thulin
Mr. Inge G. Thulin
Independent Director
Independent Director
2.93K
--
Ms. Pamela J. Craig
Ms. Pamela J. Craig
Independent Director
Independent Director
1.72K
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Robert M. (Rob) Davis
Mr. Robert M. (Rob) Davis
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
443.60K
--
Mr. Sanat Chattopadhyay
Mr. Sanat Chattopadhyay
Executive Vice President and President - Merck Manufacturing Division
Executive Vice President and President - Merck Manufacturing Division
185.33K
+17.90%
Mr. Chirfi Guindo
Mr. Chirfi Guindo
Senior Vice President, Chief Marketing Officer - Human Health
Senior Vice President, Chief Marketing Officer - Human Health
85.34K
+28.11%
Dr. Dean Y. Li, M.D., Ph.D.
Dr. Dean Y. Li, M.D., Ph.D.
Executive Vice President, President - Merck Research Laboratories
Executive Vice President, President - Merck Research Laboratories
79.59K
+0.92%
Ms. Jennifer L. Zachary
Ms. Jennifer L. Zachary
Executive Vice President, General Counsel
Executive Vice President, General Counsel
53.42K
+90.81%
Mr. Joseph Edward Romanelli
Mr. Joseph Edward Romanelli
Senior Vice President, President - MSD International Human Health
Senior Vice President, President - MSD International Human Health
22.91K
+5.27%
Desglose de ingresos
Divisa: USDActualizado: dom., 6 de jul
Divisa: USDActualizado: dom., 6 de jul
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Por negocioUSD
Nombre
Ganancia
Proporción
Oncology-Keytruda
7.21B
46.40%
Vaccines -Gardasil/Gardasil
1.33B
8.54%
Animal Health-Livestock
924.00M
5.95%
Other pharmaceutical
729.00M
4.69%
Animal Health-Companion Animals
664.00M
4.28%
Otro
4.68B
30.14%
Por regiónUSD
Nombre
Ganancia
Proporción
United States
8.52B
54.88%
Europe, Middle East and Africa
3.45B
22.24%
Latin America
792.00M
5.10%
China
702.00M
4.52%
Other
701.00M
4.51%
Otro
1.36B
8.74%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Oncology-Keytruda
7.21B
46.40%
Vaccines -Gardasil/Gardasil
1.33B
8.54%
Animal Health-Livestock
924.00M
5.95%
Other pharmaceutical
729.00M
4.69%
Animal Health-Companion Animals
664.00M
4.28%
Otro
4.68B
30.14%
Estadísticas de accionistas
Actualizado: mar., 19 de ago
Actualizado: mar., 19 de ago
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
10.08%
BlackRock Institutional Trust Company, N.A.
5.72%
State Street Global Advisors (US)
4.74%
Wellington Management Company, LLP
3.08%
Geode Capital Management, L.L.C.
2.36%
Otro
74.02%
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
10.08%
BlackRock Institutional Trust Company, N.A.
5.72%
State Street Global Advisors (US)
4.74%
Wellington Management Company, LLP
3.08%
Geode Capital Management, L.L.C.
2.36%
Otro
74.02%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
41.88%
Investment Advisor/Hedge Fund
27.00%
Research Firm
3.18%
Pension Fund
2.48%
Bank and Trust
2.34%
Sovereign Wealth Fund
1.55%
Hedge Fund
1.37%
Insurance Company
0.71%
Family Office
0.12%
Otro
19.37%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
5398
2.02B
80.82%
-16.42M
2025Q1
5446
2.05B
81.47%
-3.32M
2024Q4
5410
2.04B
80.88%
+11.87M
2024Q3
5200
2.01B
79.47%
-7.96M
2024Q2
5181
2.01B
79.28%
-4.86M
2024Q1
5154
2.00B
78.88%
-6.10M
2023Q4
5065
1.99B
78.60%
+584.81K
2023Q3
4871
1.98B
78.17%
-32.03M
2023Q2
4864
2.00B
78.94%
-18.54M
2023Q1
4818
1.99B
78.43%
-16.95M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
The Vanguard Group, Inc.
251.40M
10.01%
-1.86M
-0.73%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
147.30M
5.87%
+3.91M
+2.73%
Mar 31, 2025
State Street Global Advisors (US)
120.53M
4.8%
-379.67K
-0.31%
Mar 31, 2025
Wellington Management Company, LLP
81.67M
3.25%
+927.62K
+1.15%
Mar 31, 2025
Geode Capital Management, L.L.C.
59.66M
2.38%
-1.52M
-2.49%
Mar 31, 2025
Charles Schwab Investment Management, Inc.
49.23M
1.96%
+29.10M
+144.62%
Mar 31, 2025
Norges Bank Investment Management (NBIM)
34.98M
1.39%
+1.17M
+3.47%
Dec 31, 2024
Fidelity Management & Research Company LLC
28.25M
1.13%
-5.33M
-15.86%
Mar 31, 2025
Fisher Investments
24.45M
0.97%
+8.33M
+51.73%
Mar 31, 2025
BlackRock Asset Management Ireland Limited
22.02M
0.88%
+805.58K
+3.80%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: mié., 6 de ago
Actualizado: mié., 6 de ago
Nombre
Proporción
FT Vest DJIA Dogs 10 Target Income ETF
8.9%
First Trust NASDAQ Pharmaceuticals ETF
6.89%
First Trust Morningstar Dividend Leaders Index Fund
5.32%
LSV Disciplined Value ETF
5.24%
Invesco Dow Jones Industrial Average Dividend ETF
5.1%
Invesco Pharmaceuticals ETF
4.92%
Amplify Weight Loss Drug & Treatment ETF
4.67%
TBG Dividend Focus ETF
4.5%
VanEck Pharmaceutical ETF
4.47%
iShares U.S. Pharmaceuticals ETF
4.37%
Ver más
FT Vest DJIA Dogs 10 Target Income ETF
Proporción8.9%
First Trust NASDAQ Pharmaceuticals ETF
Proporción6.89%
First Trust Morningstar Dividend Leaders Index Fund
Proporción5.32%
LSV Disciplined Value ETF
Proporción5.24%
Invesco Dow Jones Industrial Average Dividend ETF
Proporción5.1%
Invesco Pharmaceuticals ETF
Proporción4.92%
Amplify Weight Loss Drug & Treatment ETF
Proporción4.67%
TBG Dividend Focus ETF
Proporción4.5%
VanEck Pharmaceutical ETF
Proporción4.47%
iShares U.S. Pharmaceuticals ETF
Proporción4.37%
Dividendos
Un total de
35.12B
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Jan 28, 2025
MRK.NB Interim Cash Dividend of gross USD 0.81 paid on Apr 07, 2025 going ex on Mar 17, 2025
Mar 17, 2025
Apr 07, 2025
Mar 17, 2025
Nov 19, 2024
MRK.NB Final Cash Dividend of gross USD 0.81 paid on Jan 08, 2025 going ex on Dec 16, 2024
Dec 16, 2024
Jan 08, 2025
Dec 16, 2024
Jul 23, 2024
MRK.NB Interim Cash Dividend of gross USD 0.77 paid on Oct 07, 2024 going ex on Sep 16, 2024
Sep 16, 2024
Oct 07, 2024
Sep 16, 2024
May 29, 2024
MRK.NB Interim Cash Dividend of gross USD 0.77 paid on Jul 08, 2024 going ex on Jun 17, 2024
Jun 17, 2024
Jul 08, 2024
Jun 17, 2024
Jan 23, 2024
MRK.NB Interim Cash Dividend of gross USD 0.77 paid on Apr 05, 2024 going ex on Mar 14, 2024
Mar 15, 2024
Apr 05, 2024
Mar 14, 2024
Nov 28, 2023
MRK.NB Final Cash Dividend of gross USD 0.77 paid on Jan 08, 2024 going ex on Dec 14, 2023
Dec 15, 2023
Jan 08, 2024
Dec 14, 2023
Jul 25, 2023
MRK.NB Interim Cash Dividend of gross USD 0.73 paid on Oct 06, 2023 going ex on Sep 14, 2023
Sep 15, 2023
Oct 06, 2023
Sep 14, 2023
May 23, 2023
MRK.NB Interim Cash Dividend of gross USD 0.73 paid on Jul 10, 2023 going ex on Jun 14, 2023
Jun 15, 2023
Jul 10, 2023
Jun 14, 2023
Jan 24, 2023
MRK.NB Interim Cash Dividend of gross USD 0.73 paid on Apr 10, 2023 going ex on Mar 14, 2023
Mar 15, 2023
Apr 10, 2023
Mar 14, 2023
Nov 30, 2022
MRK.NB Final Cash Dividend of gross USD 0.73 paid on Jan 09, 2023 going ex on Dec 14, 2022
Dec 15, 2022
Jan 09, 2023
Dec 14, 2022
Ver más
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
